OOIR: Observatory of International Research

Papers

(The TQCC of Movement Disorders is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Biallelic Variants in SLC27A3 Cause a Complex Form of Neurodegeneration with Brain Iron Accumulation	595
The FDA Has Ended Required Blood Monitoring for Clozapine Use—Will This Impact the Management of Parkinson's Disease Psychosis?	245
The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?	190
	143
The Pattern and Stages of Atrophy in Spinocerebellar Ataxia Type 2: Volumetrics from ENIGMA‐Ataxia	125
May Infographic	108
Movement Disorders: Volume 40, Number 6, June 2025	102
Motor Cortex Disinhibition Correlates with Olfactory Dysfunction in Parkinson's Disease	98
John Michael Walshe (April 24, 1920–October 14, 2022)	95
Movement Disorders: Volume 40, Number 2, February 2025	95
Issue Information	93
In Memoriam Mahlon R. DeLong (1938–2024)	87
Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials	83
The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease	82
Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism	79
Stability of Mosaic Divergent Repeat Interruptions in X‐Linked Dystonia‐Parkinsonism	79
Dual Task Turning in Place: A Reliable, Valid, and Responsive Outcome Measure of Freezing of Gait	78
Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy	71
Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy	70
Substantia Nigra Elasticity Measurement Using Transcranial Shear Wave Elastography: A Potential Biomarker for Parkinson's Disease	68
Safety, Tolerability, Pharmacokinetics, and Brain Target Occupancy of the OGA Inhibitor ASN90 in H	67
The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure	67
Bidirectional Transcription at the PPP2R2B Gene Locus in Spinocerebellar Ataxia Type 12	66
Fixel‐Based Analysis Reveals Whole‐Brain White Matter Abnormalities in Cervical Dystonia	63
α‐Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid‐Binding Property	62

Early Changes in Striatal Activity and Motor Kinematics in a Huntington's Disease Mouse Model	62
A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease	61
Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters	59
Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers	58
Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals	56
Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation	54
Brain–Computer Interface Improves Symptoms of Isolated Focal Laryngeal Dystonia: A Single‐Blind Study	54
Genetic Variation Analysis of Essential Tremor: Insights from the China Essential Tremor Alliance Cohort	53
Re‐emergent Tremor in Parkinson's Disease: Evidence of Pathologic β and Prokinetic γ Activity	52
AI, Technology, Telemedicine	51
Dystonia	51
Compound Heterozygous Structural Variants in Cases with Unsolved PRKN‐Associated Parkinson's Disease	51
Reply to: “Early Indian Age at Onset of Parkinson's: A Case for a Gene‐Environment Lens”	51
Friedreich's Ataxia in Colombia: A Population‐Based Study of Incidence and Socioeconomic Determinants	49
	49
Neurodevelopmental Disorder and Cortical Myoclonus in ZMYM2 Deficiency	49
	49
Patients with Allan‐Herndon‐Dudley Syndrome (MCT8 Deficiency) Display Symptoms of Parkinsonism in Childhood and Respond to Levodopa/Carbidopa Treatment	49
Movement Disorders: Volume 37, Number 9, September 2022	48
Functional Movement Disorders and Drug‐Induced Movement Disorders	48
Author Index	46
The Lows of High Reward: Choking Under Pressure	46
Obituary for Jan O. Aasly (1950–2022)	46
Derivation and Validation of a Phenoconversion‐Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder	44
Reply to: “An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis”	44
Thank you to Reviewers 2022	42
Issue Information	42
In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN‐Related Parkinson's Disease	42
Central Involvement in Pure Autonomic Failure: Insights from Neuromelanin‐Sensitive Magnetic Resonance Imaging and ¹⁸F‐Fluorodopa‐Positron Emission Tomography	41
Issue Information	41
Reply to: “Adult‐Onset Neurodegeneration in Nucleotide Excision Repair Disorders: More Common than Expected”	41
Novel In‐Frame FGF14 Deletion Causes Spinocerebellar Ataxia Type 27A: Clinical Response to Deep Brain Stimulation and 4‐Aminopyridine	41
Substantiating the Short Burst Duration in Cortical Myoclonus	40
Effect of Public Interest in Magnetic Resonance Imaging–Guided Focused Ultrasound on Enrolment for Deep Brain Stimulation	40
Genetic Determinants of Survival in Parkinson's Disease in the Asian Population	40
Diagnostic and Prognostic Value of External Anal Sphincter EMG Patterns in Multiple System Atrophy	40
Lesion of the Subthalamic Nucleus Should Not be Labeled “Subthalamotomy”; A Plea for Anatomical Accuracy and Compliance with Historical Legacy	40
Stress in Musicians with and Without Focal Dystonia Is Not Reflected in Limbic Circuit Activation	39
Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease	39
Combining Skin α‐Synuclein Real‐Time Quaking‐Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease	38
Exploration of Neurodegenerative Diseases Using Long‐Read Sequencing and Optical Genome Mapping Technologies	38
Spinal Cord Stimulation Failed to Improve Parkinson's Disease Symptoms in Randomized Crossover Double‐Blinded Evaluation	38
Navigating Visual Challenges: How Parkinson's Disease Alters Cognitive Priorities in Visual Search	38
Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation	38
De Novo and Dominantly Inherited SPTAN1 Mutations Cause Spastic Paraplegia and Cerebellar Ataxia	38
Cortical Functional Connectivity Changes in the Body‐First and Brain‐First Subtypes of Parkinson's Disease	38
Plant‐Based Dietary Patterns and Parkinson's Disease: A Prospective Analysis of the UK Biobank	37
Oligodendrocyte and Extracellular Matrix Contributions to Central Nervous System Motor Function: Implications for Dystonia	37
[ ¹¹ C ]( R )‐	36
A CGG Repeat Expansion in CSNK1E Associated wit	36

In Memoriam Gregor K. Wenning (1964–2024)	35
Research Priorities on the Role of α‐Synuclein in Parkinson's Disease Pathogenesis	35
Education, History, Disparities, Other Topics	35
Reply to: “Early Onset Nonprogressive Generalized Dystonia Is Caused by Biallelic SHQ1 Variants”	34
Prediction of Pathological Subthalamic Nucleus Beta Burst Occurrence in Parkinson's Disease	34
Movement Disorders: Volume 38, Number 12, December 2023	33
Keyword Index	33
Defining the Importance of Minor Hallucinations in Parkinson's Disease	33
Pain in Multiple System Atrophy: A Community‐Based Survey	32
Issue Information	32
Epigenetic Drug Effects in Levodopa‐Treated Patients with Parkinson's Disease	32
Neurodegeneration with Brain Iron Accumulation Disorders and Retinal Neurovascular Structure	31
A Novel SPAST Mutation Results in Spastin Accumulation and Defects in Microtubule Dynamics	31
Unusual Age‐Dependent Behavior of Leukocytes Telomere Length in Friedreich's Ataxia	31
Potential Disease‐Modifying Effects of Ganglioside GM1 Pulse Treatment on Spinocerebellar Ataxia Type 3, a Parallel‐Group, Double‐Blind, Randomized, Controlled Trial	31
Digging into the Unknowns of the Human Genome Sequence: The T2T‐CHM13 Reference Assembly Release	31
Practically Defined Off‐State Dyskinesia Following Repeated Intraputamenal Glial Cell Line–Derived Neurotrophic Factor Administration	31
Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid	30
Movement Disorders: Volume 40, Number 3, March 2025	30
Corrections to “A Machine‐Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design”	30
Static Posture Instability as a Sensitive Biomarker for Motor Abnormalities in Pre‐ataxic Spinocerebellar Ataxia Type 3 Patients	30
Ethnic Differences in Dystonia Prevalence and Phenotype	30
Free‐Water Imaging in Friedreich Ataxia Using Multi‐Compartment Models	29
Correction to “Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus”	29
Secondary Paroxysmal Kinesigenic Dyskinesia with a CASR Mutation	29
Issue Information	29
Genetic Determined Iron Starvation Signature in Friedreich's Ataxia	28
August Infographic	28
February Infographic	28
Parkinsonisms	28
Essential Tremor Suppression with a Novel Anti‐Tremor Orthosis: A Randomized Crossover Trial	28
Issue Information	27
Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson's Disease	27
Subthalamic Nucleus Activity during Cognitive Load and Gait Dysfunction in Parkinson's Disease	27
A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis	27
The Self‐Administered Screening Questionnaire for Parkinson's Disease‐Associated Psychosis (SASPAP)	27
A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ‐009	27
Whole‐Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy	27
Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy	27
Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review	27
Issue Information	27
Levodopa Disrupts Activity Patterns and Encoding of Movement in Striatal Cholinergic Interneurons of Behaving Mice	26
Structural Alterations in the Gray Matter Volume in Rapid‐Onset Dystonia‐Parkinsonism	26
Low/High Multi‐Frequency Stimulation of the Subthalamic Nucleus Improves Verbal Fluency Maintaining Motor Control in Parkinson's Disease	26
Comparison of Two α‐Synuclein Seed Amplification Assays for Discrimination of Parkinson Disease and Atypical Parkinsonism	26
¹⁸F‐Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies	25
Pallidal Evoked Resonant Neural Activity as a Candidate Biomarker for Deep Brain Stimulation in Dystonia	25
Selective Effects of Substantia Nigra and Locus Coeruleus Degeneration on Cognition in Parkinson's Disease	25
Deciphering the Janus‐Faced Nature of the Apolipoprotein Superfamily in Parkinsonian Neurodegeneration: Molecular Crosstalk Between the Astroglial Secretome and Neuronal Homeostasis	25
COVID ‐19 Infection Enhances Susceptibility to Oxidative Stress–Induced Parkinsonism	25
CAG Repeat Expansion in THAP11 Is Associated with a Novel Spinocerebellar Ataxia	25
Placebo and Nocebo Responses in Pharmacological Trials of Tic Disorders: A Meta‐Analysis	25
Unilateral Magnetic Resonance‐Guided Focused Ultrasound (MRgFUS) Pallidothalamic Tractotomy in Parkinson's Disease: Promising Results But Uncertain T	25
Genotype–Phenotype Correlations for ATX‐TBP (SCA17): MDSGene Systematic Review	25
Clearing the Smoke: What Protects Smokers from Parkinson's Disease?	24
Sex and Racial/Ethnic Differences in End‐of‐Life Care Preferences in Persons with Parkinson's Disease and Related Disorders	24
Mitochondrial DNA Copy Number as a Potential Biomarker for the Severity of Motor Symptoms and Prognosis in Parkinson's Disease	24
Patient‐Derived Neurons Exhibit α‐Synuclein Pathology and Previously Unrecognized Major Histocompatibility Complex Class I Elevation in Mitochondrial Membrane Protein–Associated Neurodegene	24
Plasma Phosphorylated Tau181 as a Biomarker for Alzheimer's Disease Co‐Pathology in Lewy Body Disease	24
Association between the Amplification Parameters of the α‐Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease	24
Classification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review	24
Early‐Onset Movement Disorder Syndrome Caused by Biallelic Variants in PDE1B Encoding Phosphodiesterase 1B	24
No Correlation between Plasma GPNMB Levels and Multiple System Atrophy in Chinese Cohorts	24
GAA ‐ FGF14 Expansions and	24
September Infographic	24
Phenotypical Differentiation of Tremor Using Time Series Feature Extraction and Machine Learning	24
Discussion of Research Priorities for Gait Disorders in Parkinson's Disease	24
Learning to Have a Long‐Duration Response	23
Reply to “Comments on ‘Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets’”	23
Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels	23
	23
Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease	23
Two London Memorials to “James Parkinson [1755–1824], Esq. Surgeon, Late of Hoxton‐Square”	23
February Infographic	23
Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease	23
Automated Motor Tic Detection: A Machine Learning Approach	23
Issue Information	22
Movement Disorders: Volume 39, Number 9, September 2024	22
First Evidence for Disease‐Modifying Treatment of SLC20A2‐Related Primary Familial Brain Calcification	22
Movement Disorders: Volume 38, Number 9, September 2023	22

Reply to: Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation	22
Reply to: “Refutation of the αSyn‐SAA‐Based Staging for Parkinson's Progression (Neuronal α‐Synuclein Disease‐Integrated Staging System [NSD‐ISS])”	22
Reply to: Enhancing Clarity in Tremor Network Gene Expression Analysis	22
Reply to: Heterogeneity of CSF1R‐RD: Genes, Environment, or Both?	22
Obituary for Professor Hiroshi Shibasaki	22
Investigating the Brain Mechanisms of Externally Cued Sit‐to‐Stand Movement in Parkinson's Disease	22
Glucocerebrosidase Target Engagement and Therapeutic Plasma and Cerebrospinal Fluid Levels After GT ‐02287 Administration in Healthy Volunteers	22
Familial Cerebellar Ataxia and Amyotrophic Lateral Sclerosis/Frontotemporal Dementia with DAB1 and C9ORF72 Repeat Expansions: An 18‐Year Study	22
Longitudinal Clinical and Biological Characteristics in Juvenile‐Onset Huntington's Disease	21
On‐Demand Cueing for Freezing of Gait in Parkinson's Disease: A Randomized Controlled Trial	21
Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings	21
Long‐Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia	21
Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations	21
Proteomic Profiling in Dystonia: The Next Frontier for Pathophysiology Research and Biomarker Exploration	21
Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease	21
Expanding the Allelic and Clinical Heterogeneity of Movement Disorders Linked to Defects of Mitochondrial Adenosine Triphosphate Synthase	21
Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study	21
Multimodal Analysis of the Visual Pathways in Friedreich's Ataxia Reveals Novel Biomarkers	21
Where Do Parkinson's Disease Patients Look While Walking?	21
Differential Synaptic Loss in β‐Amyloid Positive Versus β‐Amyloid Negative Corticobasal Syndrome	21
Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study	21
Waveform‐Based Analysis of Head Tremor Using a Marker‐Less Tracking Algorithm with 2D ‐Video: Evaluation of Sinusoidality and Rhythmicity	21
The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles?	21
Functional Magnetic Resonance Imaging (fMRI) Signatures of Progression and Phenoconversion in Prodromal Synucleinopathies	20
March Infographic	20
Movement Disorders: Volume 38, Number 11, November 2023	20
Circulating Extracellular Vesicles as a Potential Mediator of Synuclein Pathology in the Gut	20
Diffusion Tensor Imaging‐Along the Perivascular‐Space Index Is Associated with Disease Progression in Parkinson's Disease	20
Sympathetic Shift and Insular Alteration: Unravelling the Link Between Anxiety and Heart Rate Variability in Parkinson's Disease	20
Mutation Screening of TFG in α‐Synucleinopathy and Amyotrophic Lateral Sclerosis	20
A Short Progressive Supranuclear Palsy Quality of Life Scale: Data from the PSP‐NET	20
Prasinezumab: A Bayesian Perspective on Its Efficacy	20
GNAO1 Haploinsufficiency: The Milder End of the GNAO1 Phenotypic Spectrum	20
Issue Information	20
Comparative Study of Focused Ultrasound Unilateral Thalamotomy and Subthalamotomy for Medication‐Refractory Parkinson's Disease Tremor	20
Keyword Index	20
Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell‐Derived A9 Dopaminergic Neurons	20
Family History for Neurodegeneration in Multiple System Atrophy: Does it Indicate Susceptibility?	19
The Pain in Dystonia Scale (PIDS)—Development and Validation in Cervical Dystonia	19
Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA‐PD Study	19
Deep Brain Stimulation Improves Parkinson's Disease‐Associated Pain by Decreasing Spinal Nociception	19
	19
Bidirectional Interplay between Deep Brain Stimulation and Cognition in Parkinson's Disease: A Systematic Review	19
mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double‐Blind, Placebo‐Controlled Futility Trial and 1‐Year Biomarker Longitudinal Analysis	19
Atypical and Other Parkinsonisms	19
April Infographic	19
Blood‐Based α‐Synuclein Seeding—A New Era for Identifying Parkinsonian Syndromes	19
	19
Reply to: Utility of Progression Rate Since Symptom Onset in Predicting Subsequent Survival in Progressive Supranuclear Palsy	19
Diagnosis and Outcomes of Late‐Onset Wilson's Disease: A National Registry‐Based Study	19
Reply to Letter to the Editor‐MDS‐23‐0498.R2/MDS‐24‐0318.R1	19
	19
Catatonia: What Else Matters?	18
Step Width Haptic Feedback for Gait Stability in Spinocerebellar Ataxia: Preliminary Results	18
Reply to “Prevalence of NOTCH2NLC and FMR1	18
Autosomal Recessive Cerebellar Ataxias in Europe: Frequency, Onset, and Severity in 677 Patients	18
Automated Quantification of Eye Tics Using Computer Vision and Deep Learning Techniques	18
Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof‐of‐Principle Issues from a Randomized Controlled Study	18
Transforming Care Across Countries: Lessons from the Integrated Care Networks for Parkinson's Disease Study ( iCARE ‐ PD	18
Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease	18
Erythrocytic α‐Synuclein and the Gut Microbiome: Kindling of the Gut‐Brain Axis in Parkinson's Disease	18
Anodal Cerebellar Transcranial Direct Current Stimulation Reduces Motor and Cognitive Symptoms in Friedreich's Ataxia: A Randomized, Sham‐Controlled Trial	18
Brain Imaging Phenotypes Associated with Polygenic Risk for Essential Tremor	18
Pathophysiological Role of Primary Motor Cortex in Essential Tremor	18
Depressive Symptoms and Suicidal Thoughts in Restless Legs Syndrome	18
A Novel α‐Synuclein K58N Missense Variant in a Patient with Parkinson's Disease	17
Surgery Imaging and Technology	17
Dysautonomia Is Associated with Cognitive Fluctuation in Dementia with Lewy Bodies	17
An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis	17
Neurodevelopmental Gene‐Related Dystonia‐Parkinsonism with Onset in Adults: A Case with NAA15 Variant	17
Genetic Analysis of GCA Repeats in the GLS Gene: Implications for Undiagnosed Ataxia and Spinocerebellar Ataxia 3 in Mainland China	17
Aggregation‐Seeding Forms of α‐Synuclein Are Not Detected in Acute Coronavirus Disease 2019 Cerebrospinal Fluid	17
Reply to: Comment on De Giorgis et al. “Randomized Phase 3 Study of Triheptanoin for Glut1 Deficiency Syndrome–Associated Paroxysmal Movement Disorders”	17
The Dawn of Precision Medicine for Deep Brain Stimulation in Parkinson's Disease?	17
Disentangling the Connection Between Neurodevelopment and Neurodegeneration in Huntington's Disease	17
Transcranial Ultrasound Stimulation of Internal Globus Pallidus Region and Motor Cortex in Parkinson's Disease	17
No Association Between Rare TWNK Variants and Parkinson's Disease in European Cohorts	17
Globus Pallidus Internus (GPi) Neuromodulation is Not Effective in Unverricht–Lundborg Disease to Control Myoclonia	17
Further Directions in Mindfulness‐Based Interventions for Tic Disorders	17
The CM‐aGPi Network in the Generation of Tics in Tourette Syndrome	17
Issue Information	16
Movement Disorders: Volume 40, Number 7, July 2025	16
Reliability of Neuroimaging and Neurophysiological Tremor Features in Parkinson's Disease	16
Comments on: “Biallelic ELOVL1 Variants Are Linked to Hypomyelinating Leukodystrophy, Movement Disorder, and Ichthyosis”	16
A GNAI1 Pathogenic Variant in a Case with GNAO1‐Isolated Dystonia: A Modifier of Disease Severity?	16
Advancing Parkinson's Research: Considerations and Future Directions	16
Top Movement Disorders Journal Reviewers from 2024	16
A 10‐Year Community‐Based Study of Leucine‐Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease	16
Spatial Metabolic Covariance Networks in Progressive Supranuclear Palsy: Implications for Symptomatology and Their Neural Basis	16
Integrative Multi‐Omics Analysis Prioritizes Candidate Genes for Essential Tremor and Reveals a Gap Between Computational Prediction and Experimental Validation	16
High Pesticide Exposure Events and Dream‐Enacting Behaviors Among US Farmers	15
Pilot Study of Acute Behavioral Effects of Pallidal Burst Stimulation in Parkinson's Disease	15
Motor Cortical Network Excitability in Parkinson's Disease	15
Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus	15
Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome	15